Citius Oncology CTOR
NASDAQ CTOR
$0.70 +0.03 (+4.32%)
As of: Oct 21, 2026 · 11:19 AM EDT

Citius Oncology (CTOR) Receivables - Net (2025 - 2026)

Updated

Citius Oncology (CTOR) recorded Receivables - Net of $686,235 in fiscal Q3 2026 (quarter ended Jun 30, 2026), down 36.4% from the prior quarter.

Analysis

Citius Oncology (CTOR) Receivables - Net (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,133.02 Bn 1,101.60 Bn 19.71 Bn
2 Johnson & Johnson 616.49 Bn 535.01 Bn 17.26 Bn
3 AbbVie 501.09 Bn 474.20 Bn 12.70 Bn
4 Merck 366.78 Bn 321.16 Bn 12.21 Bn
5 Novartis Ag 297.96 Bn 261.95 Bn 11.24 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn
7 Amgen 235.44 Bn 190.84 Bn 7.24 Bn
8 Gilead Sciences 190.69 Bn 164.89 Bn 6.22 Bn
9 Pfizer 169.52 Bn 116.16 Bn 10.94 Bn
10 Citius Oncology 75.52 Mn 45.11 Mn 1.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 686,235.00
Mar 31, 2026 1.08 Mn
Dec 31, 2025 4.05 Mn
API Access

Citius Oncology Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=CTOR&period=max&api_key=YOUR_API_KEY